# US 2021/0171618 A1 · Multispecific antibodies that target hptp-b (ve-ptp) and vegf

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171618 A1
- Document ID: US20210171618A1
- Status: Published application
- Kind: A1
- Application number: 17/117,993
- Filed: 2020-12-10
- Published: 2021-06-10
- Earliest claimed: 2018-09-24
- Assignees: Aerpio Pharmaceuticals, Inc.
- Applicants: Aerpio Pharmaceuticals, Inc.
- Inventors: Kevin Peters
- Web page: https://patentgrep.com/patent/US20210171618A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/40: against enzymes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.

## Claims

### Claim at position 1

1-78. (canceled)

### Claim 79

A method of treating a condition in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound comprising:
(a) a first domain, wherein the first domain modulates a phosphatase, wherein the phosphatase modulates Tie2; and
(b) a second domain that specifically binds a receptor tyrosine kinase agonist.

### Claim 80 (depends on 79)

The method of claim 79, wherein the condition is an ocular condition.

### Claim 81 (depends on 79)

The method of claim 79, wherein the condition is diabetic retinopathy.

### Claim 82 (depends on 79)

The method of claim 79, wherein the condition is neovascularization.

### Claim 83 (depends on 79)

The method of claim 79, wherein the condition is vascular leak.

### Claim 84 (depends on 79)

The method of claim 79, wherein the condition is increased intraocular pressure.

### Claim 85 (depends on 79)

The method of claim 79, wherein the condition is ocular edema.

### Claim 86 (depends on 79)

The method of claim 79, wherein the condition is diabetic macular edema.

### Claim 87 (depends on 79)

The method of claim 79, wherein the condition is wet age-related macular degeneration.

### Claim 88 (depends on 79)

The method of claim 79, wherein the condition is ocular inflammation.

### Claim 89 (depends on 79)

The method of claim 79, wherein the condition is retinal vein occlusion.

### Claim 90 (depends on 79)

The method of claim 79, wherein the administration is to an eye of the subject.

### Claim 91 (depends on 79)

The method of claim 79, wherein the administration is intravitreal.

### Claim 92 (depends on 79)

The method of claim 79, wherein the administration is subcutaneous.

### Claim 93 (depends on 79)

The method of claim 79, wherein the administration is systemic.

### Claim 94 (depends on 79)

The method of claim 79, wherein the subject is a human.

### Claim 95 (depends on 79)

The method of claim 79, wherein the therapeutically-effective amount is from about 0.25 mg to about 200 mg.

### Claim 96 (depends on 79)

The method of claim 79, wherein the therapeutically-effective amount is from about 1 mg/kg to about 10 mg/kg.

### Claim 97 (depends on 79)

The method of claim 79, wherein the therapeutically-effective amount is from about 1 mg to about 50 mg.

### Claim 98 (depends on 79)

The method of claim 79, wherein the therapeutically-effective amount is from about 50 mg to about 200 mg.

### Claim 99 (depends on 79)

The method of claim 79, wherein the condition is cancer.